A new study led by researchers in the University of Toronto's Institute of Biomaterials & Biomedical Engineering (IBBME), transplanted healthy pancreatic cells under the skin to see if they would produce insulin for blood glucose control.
While noninsulin medications were not developed specifically for type 1 diabetes, they could in fact play an important role in management.
An early research study suggests that imatinib, which is a drug that suppresses the immune system , may help to preserve some beta cell function in people who are recently diagnosed with Type 1 diabetes. Imatinib, a tyrosine kinase inhibitor, is already approved for use in the treatment of Chronic Myelogenous Leukemia (CML) and several other cancers.
The European Association for the Study of Diabetes 2017 annual meeting will take place in Lisbon, Portugal from September 11-15, 2017. Some interesting research on Type 1 diabetes is on tap for the meeting, so here's a sneak preview!
Do you tend to bolus for your meal or snack during or after eating? If so, you may be unwittingly getting in your own way.
Although it didn't work wonders for blood glucose (BG) levels, liraglutide improved anthropometric and metabolic parameters without causing an increase in hypoglycemia, according to the results of a clinical trial published in July in Diabetes, Obesity, and Metabolism.
Have you ever noticed when you look at your lab results, there's a measure of kidney function called eGFR that is reported for both non-African American, and for African American? That's because there are racial and ethnic differences in kidney function decline. When it comes to A1c levels, they are higher in black people than in white people. It is debatable if this is because of poorer glycemic control, or whether there are, in fact, differences between the races in the glycation of hemoglobin.
Sotagliflozin is a drug in development, under investigation by Lexicon Pharmaceuticals and Sanofi. It is a first-in-class, oral dual inhibitor of sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2).
New research shows promise in keeping beta cell insulin production stable in those with newly diagnosed type 1 diabetes.
Answer our type 1 diabetes trivia question and win a free book!
We'd like to know what you think! Participate in our Integrated Diabetes Services monthly survey.
Wouldn't it be great if a commercially-available product existed that was derived from stem cells and could effectively replace pancreatic islet cells to allow folks who can't produce endogenous insulin to actually start making it? ViaCyte is working on turning this into a reality someday.
According to research presented at the annual meeting of the American Diabetes Association (ADA) in June, a new glucagon product is much easier to use than is the traditional formulation for injection. Could this mean that it's more likely that a caregiver would be willing to administer it when needed?
Half unit dosing with Humalog is about to become a little more convenient for insulin pen users!